Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's reliance on non-dilutive funding and limited working capital pose sustainability concerns. Competitive pressures and strategic execution risks further exacerbate these issues. Despite decreasing expenses, the potential for constrained operational flexibility and unclear management responses in the Q&A section contribute to a negative sentiment. The lack of new partnerships or strong positive catalysts, coupled with competitive pressures in a challenging market, suggests a negative stock price movement in the short term.
Key Financial Performance
Cash and Cash Equivalents $24.7 million as of December 31, 2025, with working capital of approximately $3.4 million. This was supported by $20.8 million in net proceeds from sales of common stock and non-dilutive funding including $13.6 million from the Gates Foundation, $4.5 million from ARPA-H, and $1.3 million from NIH grants.
Selling, General and Administrative (SG&A) Expenses $8.8 million for 2025, a decrease from $9.2 million in 2024. The decrease was primarily due to reductions in stock-based compensation, personnel costs, and general corporate overhead, partially offset by increased commercial readiness expenses for DARE to PLAY and professional services expenses.
Research and Development (R&D) Expenses $5.5 million for 2025, down from $14.3 million in 2024. The decrease was due to the recognition of $13.9 million in contra R&D expenses from grant funding, compared to $7.7 million in 2024. Actual R&D investment was closer between the two years when accounting for grant funding.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DARE to PLAY sildenafil cream: First-of-its-kind topical arousal cream for women, available for pre-fulfillment prescriptions in all 50 states as of February 2026. Telehealth access launched, allowing women to obtain prescriptions without in-person visits. Dispensing expected to begin in Q2 2026.
DARE to RESTORE Flora Sync LF5: A vaginal probiotic suppository designed to support vaginal microbiome balance. Expected to be commercially available in the U.S. in Q2 2026. Developed in collaboration with Probiotical and supported by clinical research.
DARE to RECLAIM: A monthly intravaginal ring delivering bioidentical estradiol and progesterone. Targeting the $2.5 billion to $4.5 billion hormone therapy market. Expected to be available for 503B prescription fulfillment in 2027.
Ovaprene: A monthly intravaginal hormone-free contraceptive candidate. Currently in Phase III pivotal trial with enrollment expected to complete in 2026. Data readout anticipated in 2027.
DARE-HPV: A potential first pharmaceutical therapeutic for high-risk HPV infections. Preparing to advance into Phase II clinical study in 2026 with ARPA-H funding.
Telehealth and digital marketing: Telehealth access and targeted digital marketing are key strategies for DARE to PLAY, enabling nationwide reach and consumer engagement.
Strategic partnerships: Plans for additional partnerships with telehealth platforms, platform distributors, and clinical networks to expand commercial footprint.
Dual path strategy: Simultaneously pursuing 503B compounding commercialization and FDA approval for products like DARE to PLAY and DARE to RECLAIM.
Grant funding: Received $13.6 million from the Gates Foundation, $4.5 million from ARPA-H, and $1.3 million from NIH grants in 2025, supporting R&D without shareholder dilution.
Focus on women's health: Exclusive focus on developing products for conditions that solely affect women, addressing significant unmet needs in areas like contraception, sexual health, and HPV.
Pipeline development: Building a robust pipeline with multiple catalysts, including first-in-category products like Ovaprene and DARE-HPV.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company faces challenges in obtaining FDA approval for its products, such as DARE to PLAY and Ovaprene, which are critical for long-term market success. The dual-path strategy of pursuing both 503B compounding and FDA approval adds complexity and potential delays.
Market Acceptance: There is uncertainty regarding the market acceptance of new products like DARE to PLAY and DARE to RESTORE. The company must prove the efficacy and safety of these products to gain trust from healthcare providers and consumers.
Supply Chain and Licensing: The 503B outsourcing facility for DARE to PLAY is still completing state licensing and other fulfillment preparations, which could delay product dispensing and revenue generation.
Financial Constraints: The company relies heavily on non-dilutive funding sources like grants, which may not be sustainable long-term. Additionally, working capital is limited, which could constrain operational flexibility.
Competitive Pressures: The company operates in a highly competitive market, particularly in women's health, where larger players may have more resources to capture market share.
Strategic Execution Risks: The company’s strategy of simultaneously advancing multiple programs and products could stretch resources and lead to execution challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
DARE to PLAY Revenue: Dispensing of DARE to PLAY sildenafil cream is expected to commence nationally in Q2 2026, with revenue generation beginning in the same quarter. The company anticipates scaling commercial and telehealth partnerships as the channel infrastructure matures.
DARE to RESTORE Launch: The first DARE to RESTORE product, Flora Sync LF5, a vaginal probiotic suppository, is expected to become commercially available in the U.S. consumer health market in Q2 2026.
DARE to RECLAIM Availability: DARE to RECLAIM, a monthly intravaginal ring delivering bioidentical estradiol and progesterone, is targeting 503B commercial availability in 2027. IND preparatory activities for a pivotal Phase III clinical study are ongoing.
Ovaprene Phase III Trial: Enrollment for the Phase III trial of Ovaprene, a monthly intravaginal hormone-free contraceptive, is expected to complete in 2026, with a data readout anticipated in 2027.
DARE-HPV Phase II Study: DARE-HPV, a potential first pharmaceutical therapeutic for high-risk HPV infections, is preparing to advance into a Phase II clinical study in 2026 with ARPA-H funding.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:When was your last interaction with FDA on sildenafil cream and what are the next steps for clinical development in the 505(b)(2) regulatory path?
A:The last interaction with the FDA was in 2025. The focus is on aligning with the FDA on the endpoints for the trial, particularly the co-primary assessment and statistical analysis plan. The dialogue with the FDA is ongoing to ensure the endpoints reflect the unmet needs and similarities between conditions.
Q:Do you need to conduct any additional safety studies, or will the submission rely on existing data for systemic sildenafil in women?
A:The existing safety data and planned Phase III data are sufficient. The topical formulation achieves the desired blood flow objectives with minimal systemic exposure, avoiding off-target effects like headache and flushing. No significant differences in adverse event profiles were observed between placebo and active groups in the Phase IIb study.
Q:What are you seeing with the order patterns so far for DARE to PLAY?
A:Prescriptions are coming in during the pre-fulfillment phase, with interest from both brick-and-mortar providers and telehealth channels. Providers are engaging early, even before dispensing begins, and the company is focusing on awareness and education campaigns. Both channels are proving to be important.
Q:How are you thinking about promoting DARE to RESTORE, which is a consumer/OTC product?
A:Promotion will leverage similar channels as DARE to PLAY, including the DARE Health Hub, digital strategies, and medical conferences. The product will also be showcased to healthcare providers, as it has peer-reviewed published data. The company is exploring opportunities for in-office availability with trusted clinicians.
Q:How do you envision the bigger driver of volume for DARE to PLAY: telehealth platforms or prescribers?
A:The company is evaluating patient acquisition costs, reach, and alignment with telehealth platforms and prescribers. They aim to ensure availability in all relevant channels while considering financial stability and cultural alignment. The focus is on smart financial structures and maximizing reach.
Q:How are you thinking about distinguishing your product from other products in the market, especially compounded sildenafil creams?
A:The company emphasizes the importance of formulation, clinical data, and time to effect. DARE to PLAY demonstrates increased blood flow within 10 minutes, unlike compounded products that require 30 minutes or more. Messaging focuses on the biotech-engineered formulation and its rapid effectiveness.
Q:Are you able to defray some of the costs of DTC advertising with partnerships?
A:Yes, the company is leveraging healthcare providers with significant followings and provider-to-provider education. They are focusing on digital education channels and trusted voices in the medical community to enhance awareness and reduce costs.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the financial structure and exact patient acquisition costs for telehealth partnerships. They also did not provide clarity on the timeline for dispensing DARE to PLAY in all 50 states or specific metrics for the success of their awareness campaigns.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARPA funding
Bioscience
DARE HPV
DARE Health
DARE prescription
DARE product
FDA therapy
GMP
Health Hub
Health care
LF
NDA submission
Phase II
Probiotical
RECLAIM
alternative
attention
custom
demand
dollar
enrollment
estradiol progesterone
fulfillment
grant funding
knowledge
minute
pathway
pharmacy
population
position
product DARE
quality
readout
risk HPV
sildenafil cream
state
story
trend
world
year
DARE Transcript
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call indicates a mixed outlook. The 25% revenue growth is positive, but the net loss and increased R&D expenses raise concerns. The dual path strategy offers potential but carries regulatory and execution risks. No new partnerships or changes in guidance were mentioned, and shareholder return plans were not discussed. Without information on market cap, a neutral sentiment is appropriate, reflecting balanced positive and negative factors.
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Unknown3-26
The company's reliance on non-dilutive funding and limited working capital pose sustainability concerns. Competitive pressures and strategic execution risks further exacerbate these issues. Despite decreasing expenses, the potential for constrained operational flexibility and unclear management responses in the Q&A section contribute to a negative sentiment. The lack of new partnerships or strong positive catalysts, coupled with competitive pressures in a challenging market, suggests a negative stock price movement in the short term.
Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals financial constraints with limited cash reserves and working capital, increased G&A expenses, and decreased R&D spending. While management is optimistic about product launches and partnerships, the market entry challenges, competitive pressures, and supply chain risks pose significant uncertainties. The Q&A section highlights the company's strategic focus but also underscores financial limitations and the need for careful execution. Overall, the negative financial health and strategic risks outweigh positive developments, leading to a negative sentiment rating.
Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed outlook. Positive factors include strategic partnerships, grant funding, and a strengthened balance sheet. However, financial constraints, regulatory hurdles, and market competition pose significant risks. The company's dual-path strategy and product pipeline are promising, but uncertainties in execution and economic conditions temper optimism. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
DARE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
